Mersana Therapeutics Inc (MRSN) — Cash Flow-to-Debt Ratio
Mersana Therapeutics Inc (MRSN) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of $-3.19 Million could theoretically repay 0% of its total liabilities ($122.22 Million) in one year. See Mersana Therapeutics Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mersana Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Mersana Therapeutics Inc across 10 annual periods. Also explore how fast is Mersana Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Mersana Therapeutics Inc (2015–2024)
Year-by-year debt coverage analysis for Mersana Therapeutics Inc. For market capitalisation and broader financial context, see market cap of Mersana Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.53x | $-82.34 Million | $154.17 Million | ▲ +40.2% |
| 2023 | -0.89x | $-168.88 Million | $189.16 Million | ▼ -338.2% |
| 2022 | -0.20x | $-49.36 Million | $242.28 Million | ▲ +87.7% |
| 2021 | -1.66x | $-139.99 Million | $84.37 Million | ▼ -0.7% |
| 2020 | -1.65x | $-74.70 Million | $45.31 Million | ▲ +28.9% |
| 2019 | -2.32x | $-67.74 Million | $29.22 Million | ▼ -192.7% |
| 2018 | -0.79x | $-55.22 Million | $69.71 Million | ▼ -12.7% |
| 2017 | -0.70x | $-42.68 Million | $60.72 Million | ▼ -457.6% |
| 2016 | 0.20x | $31.59 Million | $160.71 Million | ▲ +216.5% |
| 2015 | -0.17x | $-9.64 Million | $57.10 Million | — |